Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
isopropyl alcohol + lidocaine hydrochloride + methylprednisolone
- Development stage
- Unknown
- Lead developer
- Asclemed USA
- Modality
- Small Molecules
- Administration
- Intramuscular, Intraarticular, Intralesional, Parenteral, Topical
01
Overview
A **combination injectable kit product** containing **isopropyl alcohol** for skin antisepsis before injection, **lidocaine hydrochloride** as a local anesthetic to reduce procedural pain, and **methylprednisolone** as the principal therapeutic agent. The pharmacologically dominant component is methylprednisolone, a synthetic glucocorticoid that activates the glucocorticoid receptor to suppress inflammatory gene expression and broad immune signaling; lidocaine contributes reversible local sodium-channel blockade at the administration site, while isopropyl alcohol serves a preparatory antiseptic role rather than a systemic therapeutic one. Based on the provided context, this product appears to correspond to an unapproved combination presentation related to office-based corticosteroid injection products rather than a distinct globally established INN-branded asset, and the labeling context indicates it has not been found by FDA to be safe and effective and has not had FDA-approved labeling.
- Other names
- isopropyl alcohol + lidocaine hydrochloride + methylprednisolone
02
Targets
MR (Mineralocorticoid receptor)KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1)NaV (Voltage-gated sodium channels)GR (Glucocorticoid receptor)CaV (Voltage-gated calcium channel protein complex)
Beyond the preview
Go deeper on isopropyl alcohol + lidocaine hydrochloride + methylprednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on isopropyl alcohol + lidocaine hydrochloride + methylprednisolone.